A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder. METHOD: Of a total of 167 patients with recurrent major depression who were screened, 123 were randomly assigned to receive 400 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, double-blind, double-dummy, parallel-group, placebo- and sertraline-controlled trial. The primary efficacy analysis compared the change in score from baseline to endpoint on the 17-item Hamilton Depression Rating Scale (HAM-D) between the CP-316,311 and placebo groups. A group sequential design was used to support early trial termination based on efficacy or futility at a planned interim analysis. RESULTS: The evaluable data set for the interim analysis included 28 patients in the CP-316,311 group, 31 patients in the placebo group, and 30 patients in the sertraline group. In the interim analysis, the change from baseline in the HAM-D score at the final visit was not significantly different between the CP-316,311 and placebo groups, while change from baseline between the sertraline and placebo groups was significantly different. Given these results, futility was declared for CP-316,311 and the trial was terminated. CONCLUSIONS: Although CP-316,311 was safe and well tolerated in this study population, it failed to demonstrate efficacy in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims
Nemeroff, C. B. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300075009 · Cited by 555
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Adrenal Gland Enlargement in Major Depression: A Computed Tomographic Study
Nemeroff, C. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050048008 · Cited by 283
Nemeroff, C. B., Bissette, G., Akil, H., & Fink, M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.1.59 · Cited by 254
Research works printed but not linked: 2
- Owens MJ, 1991, Pharmacol Rev, 43, 425
- Shelton RC, 1994, Clin Ther, 16, 768
Cited by
Items 201–272 of 272
Neuropeptidergic systems in psychiatric disorders
Hodzic, S., & Riedemann, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1654292 · Cited by 2
Targeting the HPA axis in major depression: does it work?
Claes, S. J. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005983 · Cited by 4
Holsboer‐Trachsler, E., & Holsboer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_53 · Cited by 2
Psychoneuroendokrinologische Grundlagen psychischer Erkrankungen
Rupprecht, R. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_9 · Cited by 3
Neuropeptide Receptors: Novel Therapeutic Targets for Depression and Anxiety Disorders
Chaki, S., & Kanuma, K. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00300 · Cited by 1
Khattab, A., & Charlton, R. W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1127558 · Cited by 1
Wood, C. P., Gurha, A., Crook, C., Martinez, A. R., Dirik, S., Moreno, C. D., Vaiyapuri, A., Libster, A. M., Telese, F., & de Guglielmo, G. (2025) · Addiction Neuroscience · doi:10.1016/j.addicn.2025.100221 · Cited by 1
Berger, T., van Calker, D., Brakemeier, E., & Schramm, E. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22484-3.00011-6 · Cited by 1
Nagarajan, S. K., & Madhavan, T. (2015) · Journal of the Chosun Natural Science · doi:10.13160/ricns.2015.8.3.176 · Cited by 1
München, L.-M.-U. (2013) · Cited by 1
The role of the CRF-urocortin system in stress resilience
Henckens, M. J. A. G., Deussing, J. M., & Chen, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813983-7.00016-1 · Cited by 2
Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19205 · Cited by 2
Haass‐Koffler, C. L., Francis, T. C., Gandhi, P. J., Patel, R. R., Naeemuddin, M., Nielsen, C. K., Bartlett, S. E., Bonci, A., Vasile, S., Hood, B. L., et al. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.09.005 · Cited by 2
“Furthermore, 20 years of dedicated research and development efforts to advance pharmacological agents that are specific antagonists of CRF1 [12, 13] have thus far not translated to humans, with CRF1 antagonists indicating a lack of efficacy in the treatment of AUD [14, 15], major depression [16], and anxiety [17].”
BackgroundGaston, L. S., & Majzoub, J. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00013-5 · Cited by 1
Lowe, J. A., III (2013) · Wiley eBooks · doi:10.1002/9781118354483.ch7 · Cited by 1
Using Neuroscience to Guide the Development of New Pharmacotherapies for Alcoholism
Krishnan‐Sarin, S., O’Malley, S. S., & Krystal, J. H. (2009)
Neuroendokrinologische und psychoneuroimmunologische Grundlagen psychischer Erkrankungen
Rupprecht, R., & Müller, N. (2007) · Springer eBooks · doi:10.1007/978-3-540-33129-2_8
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., & Bauer, M. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50012-5
Neurobiologic Foundations of Mood Disorders
Polan, H. J., Duman, R. S., & Schatzberg, A. F. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch21
Novel Therapeutic Strategies for Bipolar Disorder
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Wiley eBooks · doi:10.1002/9780470661277.ch30 · Cited by 1
Serafini, G., Lindqvist, D., Brundin, L., Dwivedi, Y., Girardi, P., & Amore, M. (2014) · Wiley eBooks · doi:10.1002/9783527684403.ch15
Gouzien, C., Doumy, O., & Aouizerate, B. (2015) · doi:10.1016/b978-2-294-73908-8.00004-5 · Cited by 1
Rouwette, T., Vanelderen, P., Roubos, E. W., Kozicz, T., & Vissers, K. C. P. (2013) · Neuropraxis · doi:10.1007/s12474-013-0002-3
Das Corticotropin-Releasing-Hormon-System und die Angst
Refojo, D., & Deussing, J. M. (2012) · BIOspektrum · doi:10.1007/s12268-012-0135-6
CASE STUDIES IN NEUROSCIENCE: UNIQUE CHALLENGES AND EXAMPLES
Marek, G. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.008
Depression and Gene-Environment Interaction
Korean, J., Assoc, N., & Kim, Y. (2010) · 신경정신의학
The process of drug discovery and the Yin/Yang of small-molecule/biotech option
Navarra, P. (2016) · Microchemical Journal · doi:10.1016/j.microc.2016.09.015
Valdez, G. R. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_44
Schatzberg, A. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00028-4
Chronische und therapieresistente Depressionen (ICD-10 F3)
Schramm, E., Bauer, M., & Adli, M. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24904-4.00011-2
Nagarajan, S. K., & Madhavan, T. (2016) · Journal of the Chosun Natural Science · doi:10.13160/ricns.2016.9.4.241
Antidepressant Therapy for Depression: An Update
Gupta, D., & Mahesh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_17
Contributions of Genetically Defined Cell Populations in the Extended Amygdala to Emotional Behavior
Mazzone, C. M. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/mn8w-xr58
Psychoneuroendokrinologische und psychoneuroimmunologische Grundlagen psychischer Erkrankungen
Rupprecht, R., & Müller, N. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_9 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00013-3
Psychoneuroendokrinologische Grundlagen psychischer Erkrankungen
Rupprecht, R. (2015) · Springer eBooks · doi:10.1007/978-3-642-45028-0_9-1
Boateng, C. A., Schweppe, C. A., & Newman, A. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.10979-5
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd03 · Cited by 1
The CRF/Urocortin systems as therapeutic targets for alcohol use disorders
Favoretto, C. A., Bertagna, N. B., Miguel, T. T., & Quadros, I. M. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.08.002 · Cited by 1
Walderhaug, E., Krystal, J. H., & Neumeister, A. (2010) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615376667.lg03
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Conséquences pharmacologiques et fonctionnelles de l'hétérodimérisation des récepteurs V1B et CRF1
Mion, J. (2013) · theses.fr (ABES) · doi:10.70675/91d47531z8447z44d1z9f7ezf39a8e060318
Niazi, S. K. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1782364
Teneurin C-terminal associated peptide-1 attenuates chronic stress in male rats
Mueller, L. E., Siemian, J. N., Lovejoy, D. A., Stein, R. B., & Slee, A. (2026) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000886
“Nonpeptide CRF type-1 (CRF 1 ) receptor antagonists demonstrated robust anxio-lytic and antidepressant efficacy in rodent models of acute stress but failed to show clinical benefit in trials for depression and anxiety disorders (Binneman et al ., 2008; Coric et al ., 2010; Kehne and Cain, 2010).”
BindingDB (2010) · UC San Diego · doi:10.7270/q2cn740w
Erbe, S. (2009) · Qucosa (Saxon State and University Library Dresden)
Metadata
- Authors
- Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T.
- Affiliations
- Pfizer (United States) (US)
- ORCID
- Qiu, Ruolun
- Venue
- American Journal of Psychiatry
- Published
- 2008-05
- Volume
- 165
- Issue
- 5
- Pages
- 617-620
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2129752568
- Cited by
- 254
- References
- 13
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 13 · 2018: 10 · 2017: 8 · 2016: 19 · 2015: 13 · 2014: 14 · 2013: 16 · 2012: 21
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, major depressive disorder, recurrent depression, sertraline, antidepressant efficacy, drug safety and tolerability, futility, interim analysis, group sequential designs
- MeSH terms
- CRF Receptor, Type 1, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Middle Aged, Surveys and Questionnaires, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.